OnKure Therapeutics
OKUR
44 hedge funds and large institutions have $32M invested in OnKure Therapeutics in 2025 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
14% more capital invested
Capital invested by funds: $28.1M → $32M (+$3.87M)
6.39% more ownership
Funds ownership: 79.57% → 85.96% (+6.4%)
5% more funds holding
Funds holding: 42 → 44 (+2)
33% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 15
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$3.04M |
| 2 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$2.19M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$1.64M |
| 4 |
Renaissance Technologies
New York
|
+$214K |
| 5 |
Barclays
London,
United Kingdom
|
+$79.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.38M |
| 2 |
BlackRock
New York
|
-$1.53M |
| 3 |
SC
Shay Capital
New York
|
-$410K |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$323K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$320K |
OKUR Hedge Fund Activity: Q4 2025 in Review
44 of the 8,275 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q4 2025, worth a combined $32M — up 14% from $28.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new OKUR positions and 6 closed out — a net gain of 2 holders — while 10 added to existing stakes and 15 trimmed.
The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $3.04M. The largest seller was Citadel Advisors, cutting an estimated $2.38M.
- 44 institutional investors held OnKure Therapeutics (OKUR) as of Q4 2025, up from 42 in Q3 2025.
- Funds reported $32M of OnKure Therapeutics stock for Q4 2025, up 14% quarter-over-quarter.
- 8 funds opened new OnKure Therapeutics positions in Q4 2025 and 6 closed out, a net change of +2 holders.
- The largest OnKure Therapeutics buyer in Q4 2025 was ADAR1 Capital Management, an estimated $3.04M added.
- The largest OnKure Therapeutics seller in Q4 2025 was Citadel Advisors, an estimated $2.38M sold.
Based on aggregated 13F filings for Q4 2025.